Researchers at St. Michael's Hospital have published the first detailed figures showing the risk of using the prescription drug Rasilez in combination with certain other blood pressure-lowering medications. The pharmaceutical company Novartis terminated a large, international clinical trial of the drug last month after finding an increased incidence after 18-24 months of non-fatal strokes, renal complications, high levels of potassium in the blood and low blood pressure. As a result, Health Canada said on Dec. 22 that it would review the safety of Rasilez, the brand name for aliskiren...
More...
More...